A share price of Inozyme Pharma Inc [INZY] is currently trading at $6.78, up 8.83%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The INZY shares have gain 19.16% over the last week, with a monthly amount glided 10.97%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Inozyme Pharma Inc [NASDAQ: INZY] stock has seen the most recent analyst activity on March 23, 2023, when Jefferies upgraded its rating to a Buy and also boosted its price target to $6 from $4.50. Previously, Jefferies started tracking the stock with Hold rating on May 26, 2022, and set its price target to $5. On February 07, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $33 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $23 on November 29, 2021. Wedbush initiated its recommendation with a Outperform and recommended $35 as its price target on August 18, 2020. Piper Sandler started tracking with a Overweight rating for this stock on August 18, 2020, and assigned it a price target of $40. In a note dated August 18, 2020, Cowen initiated an Outperform rating.
Inozyme Pharma Inc experienced fluctuations in its stock price throughout the past year between $2.69 and $7.33. Inozyme Pharma Inc [NASDAQ: INZY] shares were valued at $6.78 at the most recent close of the market.
Analyzing the INZY fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.55 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.33 points at the first support level, and at 5.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.25, and for the 2nd resistance point, it is at 7.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Inozyme Pharma Inc [NASDAQ:INZY] is 13.36. As well, the Quick Ratio is 13.36, while the Cash Ratio is 2.36.
Transactions by insiders
Recent insider trading involved Hopfner Robert Lorne, Director, that happened on Aug 01 ’23 when 0.83 million shares were purchased. Director, Pivotal bioVenture Partners Fu completed a deal on Aug 01 ’23 to buy 0.83 million shares. Meanwhile, Director Hopfner Robert Lorne bought 0.23 million shares on May 12 ’23.
